Comparative Prognostic Value of Preoperative HALP and Cancer Inflammation Prognostic Index in Patients Undergoing Surgery for Colorectal Cancer

Background and Objectives: We compared the prognostic value of the preoperative hemoglobin–albumin–lymphocyte–platelet (HALP) index and Cancer Inflammation Prognostic Index (CIPI) after colorectal cancer surgery. Materials and Methods: This single-center retrospective study included 264 patients who underwent colorectal adenocarcinoma resection between 2014 and 2019. The primary Cox model entered both log2-transformed indices simultaneously and adjusted for age, sex, ASA class, neoadjuvant treatment, and recorded pathological stage. Discrimination was assessed using 3- and 5-year time-dependent ROC analysis and Harrell’s C-index. Cut-off-based analyses were exploratory. Results: Over a median follow-up of 86.9 months, 120 patients (45.5%) died. In the primary model, the adjusted hazard ratio per doubling was 0.822 for HALP (95% CI 0.661–1.023) and 1.058 for CIPI (95% CI 0.978–1.145). The 3-year AUCs were 0.649 for HALP and 0.699 for CIPI (p = 0.261). The 5-year AUCs were 0.631 and 0.636, respectively (p = 0.887). In exploratory analyses, the cohort-derived high-CIPI group had poorer adjusted survival (aHR 1.703, 95% CI 1.138–2.548). Both continuous indices were associated with survival in stage I–III disease, whereas neither was statistically significant in patients without neoadjuvant treatment. Conclusions: Both indices showed modest discrimination. The adjusted associations varied by model and subgroup. Incremental clinical value was not established.